The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer’s Disease: Interim Results of the ASCOMALVA Trial

Carotenuto, Anna; Rea, Raffaele; Traini, Enea; Fasanaro, Angiola Maria; Ricci, Giovanna; Manzo, Valentino; Amenta, Francesco

doi:10.3233/jad-160675

Cited by 26 publications

(15 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Causes and pathophysiology of BPSD are incompletely understood. 37 Likewise, pathophysiology, phenomenology, main clinical correlates, and long-term evolution of disinhibition symptom in dementia remain unclear. 38 Accordingly, it might be difficult to elucidate the association between memantine and improvement of disinhibition symptoms.…”

Section: Discussionmentioning

confidence: 99%

The Behavioral Effects of Combination Therapy of Memantine and Acetylcholinesterase Inhibitors Compared with Acetylcholinesterase Inhibitors Alone in Patients with Moderate Alzheimer’s Dementia: A Double-Blind Randomized Placebo-Controlled Trial

Youn

Lee

Kim

et al. 2021

Psychiatry Investig

View full text Add to dashboard Cite

the number of patients with dementia has continuously increased due to a very rapid rate of population aging. 2 According to the National Institute of Dementia, 750,488 persons were estimated to have dementia (about 10.16% of people aged 65 and over) in South Korea in 2019. 3 Social cost per year per patient with dementia was estimated at 20,420,000 Korean Won (KW; 1 USD=1,206 KW as of 2020). 3 Total public management cost for patients with dementia was estimated at 15,300 billion KW (i.e., 12,700 million USD). 3 It has been predicted that cost for patients with dementia would increase to 3 million by 2050 in South Korea. 3 Accordingly, social cost will increase rapidly.

show abstract

Section: Discussionmentioning

confidence: 99%

The Behavioral Effects of Combination Therapy of Memantine and Acetylcholinesterase Inhibitors Compared with Acetylcholinesterase Inhibitors Alone in Patients with Moderate Alzheimer’s Dementia: A Double-Blind Randomized Placebo-Controlled Trial

Youn

Lee

Kim

et al. 2021

Psychiatry Investig

View full text Add to dashboard Cite

show abstract

“…In the ASCOMALVA study, comparing a subgroup of AD individuals (n = 56) receiving a combination of donepezil and choline alphoscerate (a cholinergic precursor) versus a subgroup (n = 57) with donepezil alone (24-month treatment period), the combined treatment was more effective on apathy levels than donepezil alone (Rea et al, 2015;Carotenuto et al, 2017).…”

Section: Randomized Controlled Trials (Rct)mentioning

confidence: 99%

Pharmacologic Approaches for the Management of Apathy in Neurodegenerative Disorders

et al. 2020

View full text Add to dashboard Cite

Apathy is one of the most frequent behavioral disturbances in many neurodegenerative disorders and is known to have a negative impact on the disease progression, particularly in Alzheimer's disease. Therapeutic options are currently limited and non-pharmacological approaches should constitute first line treatments. Pharmacological agents likely to reduce apathy levels are lacking. The objective of the present article is to review recent pharmacological treatments for apathy in neurodegenerative disorders. The Pubmed database was searched with a particular focus on articles published as of January 2017. Current main levels of evidence have been reported so far with cholinergic, glutamatergic and dopaminergic agents to reduce levels of apathy, despite several conflicting results. Treatment duration and samples sizes may have however decreased the validity of previous results. Ongoing studies involving more participants/treatment duration or distinct neural pathways may provide new insights in the treatment of apathy in neurodegenerative disorders.

show abstract

“…Choline alfoscerate (alpha GPC) at a dose of 400mg TID has been found to improve cognition and global function in patients with mild to moderate AD when used over a period of 6 months [111]. This supplement, when taken with donepezil, also decreased mood symptoms in this patient population [112]. A 2010 meta-analysis found that another form of choline (CDP choline) has positive effects on several cognitive domains [113].…”

Section: Cholinementioning

confidence: 99%

Alzheimer’s Disease Prevention - A Review of Modifiable Risk Factors and the Role of Dietary Supplements

Kallas¹

2018

GGM

View full text Add to dashboard Cite

show abstract

The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer’s Disease: Interim Results of the ASCOMALVA Trial

Abstract: Patients treated with donepezil plus choline alphoscerate showed a lower level of behavioral disturbances than subjects treated with donepezil only, suggesting that the association can have beneficial effects.

Cited by 26 publications

References 62 publications

The Behavioral Effects of Combination Therapy of Memantine and Acetylcholinesterase Inhibitors Compared with Acetylcholinesterase Inhibitors Alone in Patients with Moderate Alzheimer’s Dementia: A Double-Blind Randomized Placebo-Controlled Trial

The Behavioral Effects of Combination Therapy of Memantine and Acetylcholinesterase Inhibitors Compared with Acetylcholinesterase Inhibitors Alone in Patients with Moderate Alzheimer’s Dementia: A Double-Blind Randomized Placebo-Controlled Trial

Pharmacologic Approaches for the Management of Apathy in Neurodegenerative Disorders

Alzheimer’s Disease Prevention - A Review of Modifiable Risk Factors and the Role of Dietary Supplements

Contact Info

Product

Resources

About